Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 11;5(1):00168-2018.
doi: 10.1183/23120541.00168-2018. eCollection 2019 Feb.

Pulmonary veno-occlusive disease is highly prevalent in scleroderma patients undergoing lung transplantation

Shikha Gupta  1 , Aman Gupta  2 , Sofiya Rehman  3 , Iclal Ocak  4 , Robyn T Domsic  5 , Frank Schneider  6 , M Patricia George  7
Affiliations

Pulmonary veno-occlusive disease is highly prevalent in scleroderma patients undergoing lung transplantation

Shikha Gupta et al. ERJ Open Res. .

Abstract

There is an unexpectedly high incidence of PVOD in patients with SSc-PH-ILD. Presence of PVOD may be an unrecognised contributor to the dismal prognosis of these patients. Early transplant referral should be considered for those with SSc-PH-ILD. http://ow.ly/vPvc30neJZV.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: S. Gupta has nothing to disclose. Conflict of interest: A. Gupta has nothing to disclose. Conflict of interest: S. Rehman has nothing to disclose. Conflict of interest: I. Ocak has nothing to disclose. Conflict of interest: R.T. Domsic has nothing to disclose. Conflict of interest: F. Schneider has nothing to disclose. Conflict of interest: M.P. George reports receiving personal fees from Actelion and Bayer for consulting on medical advisory boards and speaking about nonbranded, disease-specific topics; and from Gilead for speaking about nonbranded, disease-specific topics, all outside the submitted work.

Figures

FIGURE 1
FIGURE 1
a) Study profile: of 24 scleroderma (SSc) patients studied, 18 were enrolled. Of those, nine had 1+ pulmonary veno-occlusive disease (PVOD) and six had 2+ PVOD, while PVOD was absent in the remaining three. b) Pulmonary arteriole in a patient with SSc-PVOD showing changes of intimal fibrosis (red arrow). c and d) Pulmonary vein in a patient with SSc-PVOD depicting a partially arterialised vein (blue arrow) and intimal fibrosis (red arrow) consistent with changes of PVOD. PH: pulmonary hypertension.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hinchcliff M, Fischer A, Schiopu E, et al. . Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 2011; 38: 2172–2179. - PMC - PubMed
    1. Badesch DB, Champion HC, Sanchez MA, et al. . Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: Suppl., S55–S66. - PubMed
    1. Galie N, Palazzini M, Manes A. Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed. Eur Respir J 2010; 36: 986–990. - PubMed
    1. Chaisson NF, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. Chest 2013; 144: 1346–1356. - PMC - PubMed
    1. Lammi MR, Mathai SC, Saketkoo LA, et al. . Association between initial oral therapy and outcomes in systemic sclerosis-related pulmonary arterial hypertension. Arthritis Rheumatol 2016; 68: 740–748. - PMC - PubMed

LinkOut - more resources